Generic Cialis

In July 2017, Eli Lilly announced that Cialis (Tadalafil) would not be coming off patent protection in November of this year, as was expected. They arrived at a new patent settlement with multiple generic pharmaceutical companies that extended Lilly’s protection of Cialis until September 27, 2018. The agreement was reached with multiple, pharmaceutical companies and there should be some downward pressure on price due to the competition.

First approved in 2003, it has been a major source of income creating 17 billion dollars of income for Lilly.

In 2016, Cialis netted Lilly nearly 1.5 billion dollars.

Viagra’s patent protection ends in 2020. However, in an agreement with Teva pharmaceuticals, a generic will be available in December of this year. Only a single pharmaceutical company will make generic Viagra, called Sildenafil, so the pressure from competition between makers of Sildenafil will not be a factor driving down prices.

Viagra netted Pfizer a bit more than 1.5 billion dollars in 2016.